Table of Content

1. Introduction to Antibody Drug Conjugates (ADCs)
1.1 Overview
1.2 Historical Development of ADCs


2. Evolution of Antibody Drug Conjugates
2.1 Advancements in ADCs
2.1.1 First Generation
2.1.2 Second-Generation
2.1.3 Third Generation
2.2 Components of ADCs
2.2.1 Monoclonal Antibodies (mAbs)
2.2.2 Linkers
2.2.3 Payloads


3. Antibody Drug Conjugates - Mechanism of Action
3.1 Antigen - Antibody Interaction
3.2 Release of Payload
3.3 Mechanism of Cytotoxicity


4. Need of Antibody Drug Conjugates


5. Role of ADCs in Cancer Management
5.1 Breast Cancer
5.2 Leukemia
5.3 Lymphoma
5.4 Other Cancers


6. Antibody Drug Conjugates - Availability, Dosage & Price Analysis
6.1 Mylotarg
6.2 Adectris
6.3 Kadcyla
6.4 Besponsa
6.5 Lumoxiti
6.6 Polivy
6.7 Enhertu
6.8 Padcev
6.9 Trodelvy
6.10 Blenrep
6.11 Zynlonta
6.12 Tivdak
6.13 Aidixi
6.14 Ujvira
6.15 Akalux


7. Antibody Drug Conjugate - Sales Insights & Forecast 2028
7.1 Adcetris
7.2 Padcev
7.3 Tivdak
7.4 Polivy
7.5 Kadcyla
7.6 Besponsa
7.7 Enhertu
7.8 Trodelvy
7.9 Zynlonta
7.10 Blenrep


8. Global Antibody Drug Conjugate Market
8.1 Current Market Scenario
8.2 Future Market Opportunity


9. Antibody Drug Conjugate Market Regional Analysis
9.1 US
9.2 Europe
9.3 Japan
9.4 China
9.5 South Korea
9.6 India
9.7 Australia
9.8 Taiwan
9.9 Canada


10. Antibody Drug Conjugate Market by Indication
10.1 Breast Cancer
10.2 Lymphoma
10.3 Leukemia
10.4 Multiple Myeloma
10.5 Gastric Cancer
10.6 Lung Cancer


11. Global Antibody Drug Conjugates Clinical Trials Insight 2022 - 2028
11.1 By Phase
11.2 By Indication
11.3 By Company
11.4 By Patient Segment
11.5 By Country


12. Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-0
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered


13. Marketed Cancer Antibody Drug Conjugates Insight


14. Global Cancer an Antibody Drug Conjugates Market Dynamics
14.1 Favorable Parameters
14.2 Challenges for Antibody Drug Conjugates Market


15. Antibody Drug Conjugates Market - Future Outlook


16. Competitive Landscape
16.1 AstraZeneca plc
16.2 Genentech
16.3 Roche
16.4 Takeda Pharmaceuticals
16.5 Pfizer
16.6 Oxford BioTherapeutics
16.7 Heidelberg Pharma
16.8 Synthon
16.9 Mersana Therapeutics
16.10 Progenics Pharmaceuticals
16.11 Astellas Pharma
16.12 Bristol Mayer Squibb
16.13 Seattle Genetics
16.14 Immunogen
16.15 Celldex Therapeutics